Azitra Inc(AZTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AZTR Azitra Inc

Market Closed 01-23 16:00:00 EST

0.2860

+0.0020

+0.70%

盘后0.2873

+0.0013+0.45%

19:45 EST

High0.3011	Low0.2751	Vol1.90M
Open0.2856	D1 Closing0.2840	Amplitude9.15%
Mkt Cap3.07M	Tradable Cap1.54M	Total Shares10.74M
T/O545.47K	T/O Rate35.19%	Tradable Shares5.39M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AZTR","market":"US","secType":"STK","nameCN":"Azitra Inc","latestPrice":0.286,"timestamp":1769202000000,"preClose":0.284,"halted":0,"volume":1895721,"hourTrading":{"tag":"盘后","latestPrice":0.2873,"preClose":0.286,"latestTime":"19:45 EST","volume":11036,"amount":3146.6996,"timestamp":1769215551399,"change":0.0013,"changeRate":0.004545,"amplitude":0.03042},"delay":0,"changeRate":0.007042253521126768,"floatShares":5386799,"shares":10740697,"eps":-5.4871,"marketStatus":"Market Closed","change":0.002,"latestTime":"01-23 16:00:00 EST","open":0.2856,"high":0.3011,"low":0.2751,"amount":545470.9122263701,"amplitude":0.091549,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.4871,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1769418000000},"marketStatusCode":7,"adr":0,"listingDate":1684382400000,"exchange":"AMEX","adjPreClose":0.284,"preHourTrading":{"tag":"盘前","latestPrice":0.274,"preClose":0.284,"latestTime":"09:22 EST","volume":61172,"amount":17252.072450080002,"timestamp":1769178126187,"change":-0.01,"changeRate":-0.035211,"amplitude":0.045423},"postHourTrading":{"tag":"盘后","latestPrice":0.2873,"preClose":0.286,"latestTime":"19:45 EST","volume":11036,"amount":3146.6996,"timestamp":1769215551399,"change":0.0013,"changeRate":0.004545,"amplitude":0.03042},"volumeRatio":0.6653802603842772},"requestUrl":"/m/hq/s/AZTR/tweets","defaultTab":"tweets","newsList":[{"id":"2601031328","title":"Azitra Inc. to Present Clinical Strategy at Biotech Showcase in San Francisco","url":"https://stock-news.laohu8.com/highlight/detail?id=2601031328","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601031328?lang=en_us&edition=fundamental","pubTime":"2026-01-07 21:01","pubTimestamp":1767790916,"startTime":"0","endTime":"0","summary":"Azitra Inc., a clinical stage biopharmaceutical company specializing in precision dermatology, will present at the Biotech Showcase 2026 in San Francisco. The event is scheduled for Tuesday, January 13, 2026, at 2:30 PM PT, and will take place at the Hilton San Francisco Union Square, Yosemite C . Travis Whitfill, Chief Operating Officer, will represent the company, highlighting Azitra's clinical development strategy, recent achievements, and upcoming milestones.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via PR Newswire  on January 07, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDLPB4Mn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AZTR"],"gpt_icon":0},{"id":"2593448091","title":"Azitra Inc. Announces Date for Upcoming Special Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2593448091","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593448091?lang=en_us&edition=fundamental","pubTime":"2025-12-24 05:06","pubTimestamp":1766523997,"startTime":"0","endTime":"0","summary":"Azitra Inc. has scheduled a Special Meeting of Stockholders to be held virtually on February 6, 2026. The meeting will be conducted exclusively via a live audio webcast.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL3C49Jh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AZTR"],"gpt_icon":0},{"id":"2592152943","title":"BRIEF-Azitra Receives Notice Of Acceptance Of The Listing Standards Compliance Plan From NYSE American","url":"https://stock-news.laohu8.com/highlight/detail?id=2592152943","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592152943?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:11","pubTimestamp":1766005883,"startTime":"0","endTime":"0","summary":"BRIEF-Azitra Receives Notice Of Acceptance Of The Listing Standards Compliance Plan From NYSE AmericanDec 17 (Reuters) - Azitra Inc AZTR.A:AZITRA RECEIVES NOTICE OF ACCEPTANCE OF THE LISTING STANDARDS","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA5XS2TC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AZTR"],"gpt_icon":0},{"id":"2592943188","title":"Azitra Faces NYSE American Listing Compliance Deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=2592943188","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592943188?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:10","pubTimestamp":1766005814,"startTime":"0","endTime":"0","summary":"Azitra Inc. has received notice from NYSE American LLC that it was not in compliance with the minimum stockholders' equity requirement under Section 1003 of the NYSE American Company Guide, which mandates stockholders' equity of $4.0 million or more for companies with reported losses in three of the four most recent fiscal years. The Exchange has approved Azitra's plan to regain compliance with these continued listing standards. The company has also noted potential risks related to regulatory approval delays and changes in the regulatory framework that could affect its operations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via PR Newswire  on December 17, 2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL9YMF03:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1153585028.USD","LU0661504455.SGD","LU1363072403.SGD","ICE","LU2023250504.SGD","LU0390134368.USD","SG9999004303.SGD","BK4588","AZTR","LU0154245756.USD","LU0124676726.USD","BK4139","LU0648001328.SGD","LU0949170772.SGD","LU0154245673.USD","SGXZ23171101.USD","LU0256863902.USD","LU0162691827.USD","LU0417517546.SGD","LU0689626769.HKD","GB00BDT5M118.USD","LU0738911758.USD","LU0072461881.USD","LU0130102774.USD","LU0256863811.USD","LU2237957811.SGD","LU0477156953.USD","IE00BQXX3D17.EUR","LU0154236417.USD","LU1201861249.SGD","LU0980610538.SGD","LU0130517989.USD","LU0971096721.USD","BK4585","LU1917777945.USD","LU2106854487.HKD","LU2023250843.SGD","LU2237957902.USD","LU0011850046.USD","LU0314106906.USD","BK4112","IE00BQXX3C00.GBP","LU1974910355.USD","LU1506573853.SGD","IE00BQXX3F31.USD"],"gpt_icon":0},{"id":"2592439229","title":"Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan From Nyse American","url":"https://stock-news.laohu8.com/highlight/detail?id=2592439229","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592439229?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:10","pubTimestamp":1766005800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA5XS2TC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AZTR"],"gpt_icon":0},{"id":"2586399402","title":"Azitra Inc Secures $1.5M in Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2586399402","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586399402?lang=en_us&edition=fundamental","pubTime":"2025-11-26 06:24","pubTimestamp":1764109499,"startTime":"0","endTime":"0","summary":"An announcement from Azitra Inc ( ($AZTR) ) is now available. On November 24, 2025, Azitra, Inc. entered into a securities purchase agreement with ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/azitra-inc-secures-1-5m-in-private-placement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/azitra-inc-secures-1-5m-in-private-placement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AZTR"],"gpt_icon":0},{"id":"2585467023","title":"Press Release: Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2585467023","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585467023?lang=en_us&edition=fundamental","pubTime":"2025-11-24 22:00","pubTimestamp":1763992800,"startTime":"0","endTime":"0","summary":"BRANFORD, Conn., Nov. 24, 2025 /PRNewswire/ -- Azitra, Inc.  , a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 4,687,500 shares of common stock , together with warrants to purchase up to an aggregate 4,687,500 shares of common stock, in a private placement priced at a premium to market under NYSE rules . The combined effective offering price for each share of common stock  and accompanying warrant is $0.32. The warrants will have an exercise price of $0.32 per share, will be exercisable upon shareholder approval and will expire on the five-year anniversary from such date of shareholder approval.Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. Azitra's lead program, ATR-12, uses an engineered strain of S. epidermidis designe","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NYSE","AZTR"],"gpt_icon":0},{"id":"2583898705","title":"Anitra Q3 EPS $(0.67) Beats $(0.78) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583898705","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583898705?lang=en_us&edition=fundamental","pubTime":"2025-11-13 06:17","pubTimestamp":1762985867,"startTime":"0","endTime":"0","summary":"Anitra Q3 EPS $(0.67) Beats $(0.78) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48821664/anitra-q3-eps-0-67-beats-0-78-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Anitra Q3 EPS $(0.67) Beats $(0.78) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AZTR"],"gpt_icon":0},{"id":"2583589386","title":"Press Release: Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2583589386","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583589386?lang=en_us&edition=fundamental","pubTime":"2025-11-13 06:15","pubTimestamp":1762985700,"startTime":"0","endTime":"0","summary":"BRANFORD, Conn., Nov. 12, 2025 /PRNewswire/ -- Azitra, Inc.  , a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended September 30, 2025, and provided a business update.-- Dosed first patient in Phase 1/2 trial for ATR-04 program targeting. oncology patients with EGFRi-associated rash in August 2025. -- Presented positive preclinical data at BIO-Europe for ATR-01 program,\"The third quarter of 2025 was an impactful period for Azitra as we continued to progress our live biotherapeutic programs, including dosing the first patient in our Phase 1/2 trial for ATR-04 targeting oncology patients with EGFRi-associated rash,\" said Francisco Salva, CEO of Azitra. \"This candidate previously received Fast Track designation from the FDA as there is an incredible opportunity to help alleviate a major dermatologic toxicity associated with EGFR inhibitor treatments, which impacts approximate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AZTR","BK4022","BK4232","R"],"gpt_icon":0},{"id":"2583958641","title":"Azitra posts Q3 net loss of $2.8 million on $1.4 million cash balance","url":"https://stock-news.laohu8.com/highlight/detail?id=2583958641","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583958641?lang=en_us&edition=fundamental","pubTime":"2025-11-13 06:02","pubTimestamp":1762984963,"startTime":"0","endTime":"0","summary":"Azitra Inc. reported a net loss of $2.8 million for the quarter ended September 30, 2025, compared to a net loss of $1.0 million in the same period in 2024. Research and development expenses rose to $1.2 million from $1.0 million, while general and administrative expenses decreased to $1.6 million from $1.9 million year-over-year. As of September 30, 2025, the company held $1.4 million in cash and cash equivalents. During the quarter, Azitra raised $2.8 million in gross proceeds through its equity line of credit with Alumni Capital LP. Key business developments included dosing the first patient in a Phase 1/2 trial for the ATR-04 program and presenting positive preclinical data for the ATR-01 program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL7MRFjp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZTR","BK4139"],"gpt_icon":0},{"id":"2581001649","title":"BRIEF-Azitra, Inc. Addresses False Report Regarding Sale Of Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2581001649","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581001649?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:17","pubTimestamp":1762514276,"startTime":"0","endTime":"0","summary":"BRIEF-Azitra, Inc. Addresses False Report Regarding Sale Of SecuritiesNov 7 (Reuters) - Azitra Inc AZTR.A:AZITRA, INC. ADDRESSES FALSE REPORT REGARDING SALE OF SECURITIESAZITRA - REPORT CIRCULATED CLA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nTUAVNGCZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZTR","BK4139"],"gpt_icon":0},{"id":"2581009481","title":"Azitra Inc - Taking Steps to Identify Source of False Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2581009481","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581009481?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:00","pubTimestamp":1762513203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nTUAVNGCZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AZTR","BK4139"],"gpt_icon":0},{"id":"2581009413","title":"Azitra - Report Circulated Claiming That Co Priced a $44 Million Registered Direct Offering Is False and Should Not Be Relied Upon","url":"https://stock-news.laohu8.com/highlight/detail?id=2581009413","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581009413?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:00","pubTimestamp":1762513203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nTUAVNGCZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AZTR"],"gpt_icon":0},{"id":"2576599908","title":"Azitra Unveils Positive Preclinical Results for ATR-01 in Ichthyosis Vulgaris","url":"https://stock-news.laohu8.com/highlight/detail?id=2576599908","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576599908?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:02","pubTimestamp":1760961759,"startTime":"0","endTime":"0","summary":"Azitra, Inc. has announced positive preclinical data for its ATR-01 program, which is being developed as a potential treatment for ichthyosis vulgaris. ATR-01 utilizes an engineered strain of S. epidermidis  designed to secrete functional human filaggrin protein. Preclinical results demonstrated that ATR01-616 can produce active filaggrin, deliver it through the human stratum corneum, and repair damaged model skin. Specifically, the strain reduced transepidermal water loss in ex vivo pig skin models and showed positive pharmacological activity in multiple preclinical tests. Detailed data from these studies will be presented virtually at the BIO-Europe conference, scheduled to take place in Vienna, Austria, from November 3-5, 2025. Azitra also provided updates on its clinical programs ATR-12 and ATR-04, with further information on the ATR-01 program and its path to first-in-human studies expected in 2026.Disclaimer: This news brief was created by Public Technologies  using generative ar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL8ZFDBv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AZTR"],"gpt_icon":0},{"id":"2576859912","title":"Azitra- Atr-01 Preclinical Data Show Production of Active, Functional Filaggrin Delivered Through Human Stratum Corneum & Repair of Damaged Model Skin","url":"https://stock-news.laohu8.com/highlight/detail?id=2576859912","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576859912?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:02","pubTimestamp":1760961752,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nFWN3VZ044:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AZTR"],"gpt_icon":0},{"id":"2576599698","title":"Azitra, Inc. Announces Positive Preclinical Data for Atr-01 Program, Designed to Treat Ichthyosis Vulgaris","url":"https://stock-news.laohu8.com/highlight/detail?id=2576599698","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576599698?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:02","pubTimestamp":1760961752,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nFWN3VZ044:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AZTR"],"gpt_icon":0},{"id":"2572604636","title":"Azitra Inc Faces NYSE Compliance Deadline Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2572604636","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572604636?lang=en_us&edition=fundamental","pubTime":"2025-10-04 05:17","pubTimestamp":1759526266,"startTime":"0","endTime":"0","summary":"Azitra Inc ( ($AZTR) ) has provided an update. On October 1, 2025, Azitra, Inc. received a notice from NYSE American LLC regarding non-compliance w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/azitra-inc-faces-nyse-compliance-deadline-notice?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/azitra-inc-faces-nyse-compliance-deadline-notice?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NYSE","AZTR"],"gpt_icon":0},{"id":"2572354186","title":"Azitra Inc. Receives NYSE American Non-Compliance Notice Over Stockholders’ Equity Requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=2572354186","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572354186?lang=en_us&edition=fundamental","pubTime":"2025-10-04 04:59","pubTimestamp":1759525181,"startTime":"0","endTime":"0","summary":"Azitra Inc. , a clinical-stage biopharmaceutical company specializing in precision dermatology, announced that it has received a notice of non-compliance from the NYSE American stock exchange. The notice states that Azitra does not meet the continued listing requirement of maintaining at least $4 million in stockholders' equity, as outlined in Section 1003 of the NYSE American Company Guide, due to reported net losses in three of its last four fiscal years. Azitra has until October 31, 2025, to submit a plan to the exchange outlining steps to regain compliance by April 1, 2027. The notice does not immediately affect the trading or listing of Azitra's shares, nor its business operations or SEC reporting requirements. Azitra is currently exploring multiple funding options to address the issue.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nNDL6ZFBPM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AZTR"],"gpt_icon":0},{"id":"2572741635","title":"Azitra receives noncompliance notification from NYSE","url":"https://stock-news.laohu8.com/highlight/detail?id=2572741635","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572741635?lang=en_us&edition=fundamental","pubTime":"2025-10-04 04:55","pubTimestamp":1759524906,"startTime":"0","endTime":"0","summary":"Azitra (AZTR) announced it received a notice from the staff of the NYSE that Azitra was not in compliance with the exchange’s continued listing sta...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/azitra-receives-noncompliance-notification-from-nyse-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/azitra-receives-noncompliance-notification-from-nyse-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NYSE","BK4139","AZTR"],"gpt_icon":0},{"id":"2572068172","title":"Azitra Inc.’s ATR-04 Study: A Potential Game-Changer for Rash Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2572068172","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572068172?lang=en_us&edition=fundamental","pubTime":"2025-10-04 00:30","pubTimestamp":1759509017,"startTime":"0","endTime":"0","summary":"Azitra Inc (($AZTR)) announced an update on their ongoing clinical study. Azitra Inc. recently updated its clinical study titled A Phase 1b/2a, Mul...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/azitra-inc-s-atr-04-study-a-potential-game-changer-for-rash-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/azitra-inc-s-atr-04-study-a-potential-game-changer-for-rash-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AZTR","BK4139","ATR","BK4126"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.azitrainc.com","stockEarnings":[{"period":"1week","weight":-0.128},{"period":"1month","weight":-0.088},{"period":"3month","weight":-0.4982},{"period":"6month","weight":-0.8011},{"period":"1year","weight":-0.8297},{"period":"ytd","weight":0.0801}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":-0.0017},{"period":"3month","weight":0.0177},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.0107}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.","exchange":"AMEX","name":"Azitra Inc","nameEN":"Azitra Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Azitra Inc(AZTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Azitra Inc(AZTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Azitra Inc,AZTR,Azitra Inc股票,Azitra Inc股票老虎,Azitra Inc股票老虎国际,Azitra Inc行情,Azitra Inc股票行情,Azitra Inc股价,Azitra Inc股市,Azitra Inc股票价格,Azitra Inc股票交易,Azitra Inc股票购买,Azitra Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Azitra Inc(AZTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Azitra Inc(AZTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction